Mayzent generics — when can they launch?
Mayzent (SIPONIMOD) · Novartis · 15 active US patents · 0 expired
Where Mayzent sits in the generic timeline
Imminent generic cliff: earliest active US patent for Mayzent expires in 2028 (~2 years from today). ANDA filers are likely already preparing Paragraph IV certifications. Expect first-filer 180-day exclusivity competition imminently.
Under US Hatch-Waxman, a generic enters via an ANDA (Abbreviated New Drug Application) and may file with one of four Paragraph IV certifications attacking the brand's listed patents. If the brand sues within 45 days, a 30-month FDA approval stay is triggered. First Para IV filer typically gets 180-day market exclusivity.
Patent estate by type — active patents
Method-of-use patents only carve out specific indications; generics can launch with a "skinny label" omitting those uses. Composition-of-matter patents block the molecule itself.
- Method of Use — 9 patents
- Composition of Matter — 3 patents
- Formulation — 3 patents
FDA U-codes carved out by Mayzent patents
Method-of-use patents are listed against specific FDA Patent Use Codes ("U-codes") representing carved-out indications. Generics can launch with a label that omits these uses.
| U-code | Description |
|---|---|
U-2511 | (no description) |
U-3889 | (no description) |
U-4407 | (no description) |
Sample patent estate
Showing 6 of 15 active US patents. View full estate on the Mayzent drug page →
-
This patent protects a novel class of immunosuppressant compounds useful in treating or preventing diseases mediated by lymphocyte interactions.USPTO title: Immunosuppresant compounds and compositions
-
This patent protects a novel class of immunosuppressant compounds useful in treating or preventing diseases mediated by lymphocyte interactions.USPTO title: Immunosuppresant compounds and compositions
-
This patent protects a novel class of immunosuppressant compounds useful in treating or preventing diseases mediated by lymphocyte interactions.USPTO title: Immunosuppresant compounds and compositions
-
This patent protects a dosage regimen for an S1P receptor agonist, where the initial daily dosage is lower than the standard daily dosage.USPTO title: Dosage regimen of an S1P receptor agonist
-
This patent protects a dosage regimen for an S1P receptor agonist, where the initial daily dosage is lower than the standard daily dosage.USPTO title: Dosage regimen of an S1P receptor agonist
-
This patent protects a dosage regimen for an S1P receptor agonist, where the initial daily dosage is lower than the standard daily dosage.USPTO title: Dosage regimen of an S1P receptor agonist
Sources
- FDA Orange Book — patents listed against Mayzent (NDA filed 2019)
- Mayzent drug profile — full patent estate, indications, clinical trials, pricing
- Novartis patent portfolio
- Patent cliff 2028 — every drug losing US exclusivity that year
Patent term extensions (PTR, pediatric exclusivity), Hatch-Waxman 30-month stays, and FDA regulatory exclusivity (NCE/ODE/PED) may shift the effective generic entry date. Not legal advice.
Get generic entry alerts
Free Pharma CI alerts on Mayzent — get notified the moment an ANDA Paragraph IV certification is filed, a 30-month stay is triggered, or a generic launches. First 2 drugs free.
Subscribe free →